G Tallini

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group
    Giovanni Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, USA
    J Pathol 196:194-203. 2002
  2. ncbi Molecular pathobiology of thyroid neoplasms
    Giovanni Tallini
    Department of Pathology Yale University School of Medicine, New Haven, CT 06510, USA
    Endocr Pathol 13:271-88. 2002
  3. ncbi HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Lab Invest 80:359-69. 2000
  4. ncbi Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Lab Invest 79:547-55. 1999
  5. ncbi Oncocytic tumours
    G Tallini
    Department of Pathology, Yale New Haven Hospital, CT 06510, USA
    Virchows Arch 433:5-12. 1998
  6. ncbi Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    J Clin Oncol 16:1158-66. 1998
  7. ncbi RET oncogene activation in papillary thyroid carcinoma
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Adv Anat Pathol 8:345-54. 2001
  8. ncbi Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma
    G Garcia-Rostan
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 59:1811-5. 1999
  9. ncbi RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 4:287-94. 1998
  10. ncbi Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases
    E Salloum
    Department of Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, CT 06520 8032
    J Clin Oncol 14:1943-9. 1996

Collaborators

Detail Information

Publications49

  1. ncbi Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group
    Giovanni Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, USA
    J Pathol 196:194-203. 2002
    ..They are associated with malignancy/tumour grade as well as with specific diagnoses in many cases, and can therefore be of potential value for tumour typing...
  2. ncbi Molecular pathobiology of thyroid neoplasms
    Giovanni Tallini
    Department of Pathology Yale University School of Medicine, New Haven, CT 06510, USA
    Endocr Pathol 13:271-88. 2002
    ....
  3. ncbi HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Lab Invest 80:359-69. 2000
    ....
  4. ncbi Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Lab Invest 79:547-55. 1999
    ..The lack of Ras mutations in the 9 oncocytic neoplasms exhibiting chromosomal aneuploidy indicates that numerical chromosomal abnormalities are independent of activating Ras mutations in oncocytic tumors...
  5. ncbi Oncocytic tumours
    G Tallini
    Department of Pathology, Yale New Haven Hospital, CT 06510, USA
    Virchows Arch 433:5-12. 1998
    ....
  6. ncbi Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    J Clin Oncol 16:1158-66. 1998
    ..Detection of mRNA transcripts for thyroglobulin (TG), thyroid peroxidase (TPO) and RET/PTC1 in the peripheral blood of patients with thyroid disease...
  7. ncbi RET oncogene activation in papillary thyroid carcinoma
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Adv Anat Pathol 8:345-54. 2001
    ..The proposed mechanisms of RET/PTC-induced tumorigenesis and the clinical and pathologic implications of RET/PTC activation are discussed...
  8. ncbi Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma
    G Garcia-Rostan
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 59:1811-5. 1999
    ..These findings support the idea that beta-catenin acts as an oncogene and contributes to the highly aggressive behavior of this tumor...
  9. ncbi RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
    G Tallini
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 4:287-94. 1998
    ....
  10. ncbi Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases
    E Salloum
    Department of Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, CT 06520 8032
    J Clin Oncol 14:1943-9. 1996
    ....
  11. pmc Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis
    G Garcia-Rostan
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Am J Pathol 158:987-96. 2001
    ..Analysis of beta-catenin dysregulation may be useful to objectively subtype thyroid neoplasms and more accurately predict outcomes...
  12. ncbi Recurrent chromosome aberrations in fibrous dysplasia of the bone: a report of the CHAMP study group. CHromosomes And MorPhology
    P Dal Cin
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cancer Genet Cytogenet 122:30-2. 2000
    ....
  13. ncbi Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation
    D Q Zheng
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Biol Chem 275:24565-74. 2000
    ....
  14. ncbi Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women
    Yawei Zhang
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer Causes Control 15:419-28. 2004
    ..To further investigate the role of prior medical conditions and medication use in the etiology of non-Hodgkin lymphoma (NHL), we analyzed the data from a population-based case-control study of NHL in Connecticut women...
  15. pmc The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma
    Rosa Marina Melillo
    Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facolta di Medicina e Chirurgia, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Am J Pathol 165:511-21. 2004
    ..In conclusion, RET point mutants can behave as dominant oncogenes for thyroid follicular cells. Their transforming activity, however, is rather modest, providing a possible explanation for the rare association of MTC with PTC...
  16. ncbi Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women
    Yawei Zhang
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA
    Am J Epidemiol 160:325-30. 2004
    ..In summary, the authors' findings do not support the hypothesis that allogeneic blood transfusion increases the risk of non-Hodgkin's lymphoma...
  17. ncbi Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women
    Yawei Zhang
    Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA
    Am J Epidemiol 160:766-73. 2004
    ..These findings support a reduced risk of non-Hodgkin's lymphoma associated with multiple pregnancies and an increased risk of non-Hodgkin's lymphoma associated with later age at menarche...
  18. ncbi Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma
    Kerry J Rhoden
    JB Pierce Laboratory, Yale University School of Medicine, New Haven, CT, USA
    Lab Invest 84:1557-70. 2004
    ....
  19. ncbi Assessment of RET/PTC oncogene activation in thyroid nodules utilizing laser microdissection followed by nested RT-PCR
    Giovanni Tallini
    Division of Pathology, Yale University School of Medicine, New Haven, CT, USA
    Methods Mol Biol 293:103-11. 2005
    ..Rearrangements of the RET oncogene have been proposed as a marker for papillary thyroid cancer. In this chapter, methods for the analysis of the RET oncogene in laser microdissected papillary thyroid cancer tissue are described...
  20. ncbi HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor
    Pei Hui
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Mod Pathol 18:1519-26. 2005
    ..In summary, expression of HMGA2 is a feature of MPNST but not of synovial sarcoma and immunohistochemical staining of HMGA2 may be a useful marker to separate malignant peripheral nerve sheath tumor from synovial sarcoma...
  21. ncbi RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma
    Kerry J Rhoden
    Ospedale Bellaria, Via Altura 3, 40139 Bologna, Italy
    J Clin Endocrinol Metab 91:2414-23. 2006
    ....
  22. ncbi Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer
    Shuiying Hu
    Department of Medicine, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Cancer 119:2322-9. 2006
    ..These results suggest that aberrant methylation and hence silencing of TIMP3, SLC5A8, DAPK and RARbeta2, in association with BRAF mutation, may be an important step in PTC tumorigenesis and progression...
  23. ncbi Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings
    Daniela V Frau
    Dipartimento di Scienze e Tecnologie Biomediche, University of Cagliari, 09042 Monserrato CA, Italy
    J Clin Endocrinol Metab 93:177-81. 2008
    ..Follicular thyroid carcinomas are often aneuploid and may exhibit t(2;3)(q13;p25), resulting in PAX8-PPARgamma1 gene fusion. Isolated trisomy 17 has rarely been reported in thyroid lesions, and its significance is unknown...
  24. ncbi Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women
    Lindsay McOmber Morton
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 13:425-30. 2004
    ..To further investigate the link between HCV and NHL, we conducted HCV testing on serum samples of 998 women (464 cases; 534 controls) from a population-based case-control study of women in Connecticut...
  25. ncbi Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity
    Jeffrey Liu
    Department of Otolaryngology Head and Neck Surgery, Columbia University, New York, New York, USA
    Cancer 107:1255-64. 2006
    ..The objective of this study was to assess the behavior of FVPTC, especially its encapsulated form, and shed more light on its true position in the classification scheme of well differentiated thyroid carcinoma...
  26. ncbi Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women
    Tongzhang Zheng
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
    Am J Epidemiol 159:454-66. 2004
    ..The antioxidant or inhibiting nitrosation reaction properties of vegetables and fruits may result in a reduced risk. Further investigation of the role of dietary intakes on the risk of NHL is warranted...
  27. ncbi RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma
    Marina N Nikiforova
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0529, USA
    J Clin Endocrinol Metab 88:2318-26. 2003
    ..These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPAR gamma rearrangement...
  28. ncbi Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity
    Ning Li
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06504 8900, USA
    Am J Dermatopathol 26:267-72. 2004
    ..001). We conclude that HMGA1 and HMGA2 expression can be used to distinguish DF from DFSP with a degree of accuracy that is fully equivalent to that of Factor XIIIa and CD34...
  29. pmc Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer
    Alfredo Fusco
    Centro di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche c o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    Am J Pathol 160:2157-67. 2002
    ....
  30. ncbi Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States)
    Lindsay McOmber Morton
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Causes Control 14:687-94. 2003
    ..Data from a population-based case-control study among women in Connecticut were analyzed to determine the potential impact of alcohol consumption on risk of NHL...
  31. ncbi RET activation and clinicopathologic features in poorly differentiated thyroid tumors
    Massimo Santoro
    Centro di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:370-9. 2002
    ....
  32. ncbi Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes
    Maria Domenica Castellone
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, c o Dipartimento di Biologia, University Federico II, Naples, Italy
    Oncogene 22:246-55. 2003
    ..In turn, Y1062 phosphorylation transmits not only mitogenic but also proapoptotic signals to thyroid cells...
  33. ncbi Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR
    Luca Morandi
    Department of Oncology, Section of Pathology, University of Bologna, Ospedale Bellaria, Bologna, Italy
    J Virol Methods 140:148-54. 2007
    ....
  34. ncbi Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer
    Peng Hou
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 13:1161-70. 2007
    ..To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer...
  35. ncbi Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 64:1664-8. 2004
    ....
  36. pmc Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors
    Giuseppe Gasparre
    Unità di Genetica Medica, Policlinico Universitario S Orsola Malpighi, University of Bologna, 40126 Bologna, Italy
    Proc Natl Acad Sci U S A 104:9001-6. 2007
    ..We conclude that disruptive mutations in complex I subunits are markers of thyroid oncocytic tumors...
  37. ncbi Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications
    Ronald A Ghossein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 17:655-61. 2007
    ..To assess the biologic and clinical behavior of TCV without ETE, we performed a detailed comparative clinicopathologic analysis of classical PTC and TCV without ETE...
  38. ncbi Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III
    Elena Bonora
    Unità di Genetica Medica, Policlinico Universitario S Orsola Malpighi, Italy
    Cancer Res 66:6087-96. 2006
    ..UC1 is due to a combined complex I/III defect associated with mtDNA mutations, as proven by the transfer of the defective energetic phenotype with the mitochondrial genome into the cybrids...
  39. ncbi BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:6373-9. 2005
    ..Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer...
  40. ncbi Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing
    Mingzhao Xing
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 63:2316-21. 2003
    ..We propose that methylation of TSHR may provide a novel diagnostic marker of malignancy and a basis for potential use of demethylating agents in conjunction with TSH-promoted radioiodine therapy for epithelial thyroid cancers...
  41. ncbi Systemic Tropheryma whippleii infection associated with monoclonal B-cell proliferation: a Helicobacter pylori-type pathogenesis?
    Sa Wang
    Department of Pathology, Yale University School of Medicine, New Haven, Conn, USA
    Arch Pathol Lab Med 127:1619-22. 2003
    ..The monoclonal B cells have persisted in blood for the entire follow-up period (10 months). The possibility of reactive monoclonal B-cell proliferation versus Whipple disease-related B-cell lymphoma is discussed...
  42. ncbi Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker
    Volkert B Wreesmann
    Laboratory of Epithelial Cancer Biology, Head and Neck Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 64:3780-9. 2004
    ..3; 95% confidence interval, 1.1-5.5; P = 0.03). Our data suggest that MUC1 dysregulation is associated with aggressive behavior of PTC and may serve as a prognostic marker and potential therapeutic target in this disease...
  43. ncbi Three-dimensional reconstruction of vessel distribution in benign and malignant lesions of thyroid
    Maria P Foschini
    Department of Anatomic Pathology, University of Bologna Ospedale Bellaria, Bologna, Italy
    Virchows Arch 445:189-98. 2004
    ..Vascular anastomoses and intratumoural vessels surrounding solid avascular areas are signs of malignancy...
  44. ncbi Nuclear alterations and RET/PTC activation
    Vincenzo Eusebi
    Am J Surg Pathol 28:974-5. 2004
  45. ncbi Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations
    Tinuccia Dettori
    Department of Biomedical Sciences and Technology, University of Cagliari, Cagliari, Italy
    Genes Chromosomes Cancer 38:22-31. 2003
    ..Our data support the contention that follicular tumors composed of oncocytes should be regarded as a distinct subset...
  46. ncbi Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry
    Pei Hui
    Department of Laboratory Medicine, Yale University School of Medicine, 333 Cedar Street, P O Box 208035, New Haven, CT 06520 8035, USA
    Leuk Lymphoma 44:1385-94. 2003
    ....
  47. ncbi ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer
    Ginesa Garcia-Rostan
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    J Clin Oncol 21:3226-35. 2003
    ..ras oncogenic activation has long been demonstrated in thyroid carcinomas of follicular cell derivation, but no consistent relationship has been shown between mutations and clinicopathologic features...
  48. ncbi Tumor-specific changes in mtDNA content in human cancer
    Elizabeth Mambo
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Int J Cancer 116:920-4. 2005
    ..Our findings suggest that mtDNA content can be used as a molecular diagnostic tool to help identify genetic abnormalities in human tumors...
  49. ncbi Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation
    Giuseppe Floris
    Laboratory for Morphology and Molecular Pathology, University of Leuven, Belgium
    Diagn Mol Pathol 16:243-8. 2007
    ..This finding supports the oncogenic properties of the HMGA family of proteins and their role in the process of malignant transformation...